Everence Capital Management Inc. Acquires New Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

Everence Capital Management Inc. acquired a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 3,060 shares of the company's stock, valued at approximately $557,000.

A number of other hedge funds have also recently added to or reduced their stakes in KRYS. Goldman Sachs Group Inc. grew its stake in shares of Krystal Biotech by 23.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 228,053 shares of the company's stock worth $28,292,000 after purchasing an additional 43,709 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Krystal Biotech by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 2,435,774 shares of the company's stock worth $302,182,000 after acquiring an additional 35,632 shares during the last quarter. Hennion & Walsh Asset Management Inc. lifted its stake in shares of Krystal Biotech by 5.6% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 33,154 shares of the company's stock worth $5,899,000 after acquiring an additional 1,756 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in Krystal Biotech by 167.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 158,425 shares of the company's stock valued at $28,189,000 after acquiring an additional 99,101 shares during the last quarter. Finally, Principal Financial Group Inc. increased its position in Krystal Biotech by 2.8% during the 1st quarter. Principal Financial Group Inc. now owns 5,959 shares of the company's stock valued at $1,060,000 after purchasing an additional 160 shares during the period. Institutional investors and hedge funds own 86.29% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. William Blair raised shares of Krystal Biotech to a "strong-buy" rating in a research note on Friday, August 30th. Chardan Capital boosted their price objective on Krystal Biotech from $153.00 to $208.00 and gave the company a "buy" rating in a research note on Monday, August 5th. Cantor Fitzgerald restated an "overweight" rating on shares of Krystal Biotech in a research report on Thursday, August 29th. HC Wainwright lifted their target price on Krystal Biotech from $200.00 to $221.00 and gave the stock a "buy" rating in a report on Wednesday, August 28th. Finally, Stifel Nicolaus increased their price target on Krystal Biotech from $204.00 to $220.00 and gave the stock a "buy" rating in a report on Wednesday, September 11th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Krystal Biotech has an average rating of "Buy" and a consensus target price of $196.75.

Krystal Biotech Stock Down 2.1 %

KRYS stock traded down $3.78 during midday trading on Tuesday, reaching $175.20. 142,907 shares of the company's stock traded hands, compared to its average volume of 334,448. Krystal Biotech, Inc. has a 52 week low of $93.95 and a 52 week high of $219.34. The company has a market cap of $5.00 billion, a price-to-earnings ratio of 93.69 and a beta of 0.82. The firm's fifty day moving average price is $186.32 and its 200-day moving average price is $180.06.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings results on Monday, August 5th. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.03. The business had revenue of $70.28 million for the quarter, compared to analysts' expectations of $65.27 million. Krystal Biotech had a net margin of 63.73% and a return on equity of 1.99%. The firm's revenue for the quarter was up 70283900.0% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.25) EPS. Analysts forecast that Krystal Biotech, Inc. will post 3.13 earnings per share for the current year.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the completion of the sale, the insider now directly owns 1,500,882 shares of the company's stock, valued at approximately $296,814,424.32. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 14.10% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).